Rallybio Corporation (RLYB)

Market Cap	69.20M
Revenue (ttm)	n/a
Net Income (ttm)	-74.56M
Shares Out	37.81M
EPS (ttm)	-1.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	224,274
Open	1.870
Previous Close	1.830
Day's Range	1.780 - 1.890
52-Week Range	1.225 - 9.140
Beta	-1.64
Analysts	Buy
Price Target	10.42 (+469.4%)
Earnings Date	May 14, 2024

About RLYB

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical devel...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 29, 2021
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: RLYB

Analyst Forecast

According to 6 analysts, the average rating for RLYB stock is "Buy." The 12-month stock price forecast is $10.42, which is an increase of 469.40% from the latest price.

Price Target

$10.42

(469.40% upside)

Analyst Consensus: Buy